Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Survivin and leukemia.

Xiu Li Cong1, Zhong Chao Han

  • 1State Key Laboratory of Experimental Hematology, Institute of Hematology and Hospital of Blood Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.

International Journal of Hematology
|November 16, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Comparison of the Biological Functions between Human Bone Marrow Derived CD106 <sup>+</sup>Mesenchymal Stem Cells and CD106 <sup>-</sup> Subgroup].

Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae·2019
Same author

Heterogeneity of Human Mesenchymal Stromal/Stem Cells.

Advances in experimental medicine and biology·2019
Same author

[Effect of CD106<sup>+</sup> Mesenchymal Stem Cell on Bone Marrow Vascular Failure in Patients with Aplastic Anemia].

Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae·2018
Same author

Human umbilical cord mesenchymal stem cells increase interleukin-9 production of CD4<sup>+</sup> T cells.

Experimental and therapeutic medicine·2017
Same author

Heterogeneity of proangiogenic features in mesenchymal stem cells derived from bone marrow, adipose tissue, umbilical cord, and placenta.

Stem cell research & therapy·2016
Same author

Transplantation of Human Placenta-Derived Mesenchymal Stem Cells Alleviates Critical Limb Ischemia in Diabetic Nude Rats.

Cell transplantation·2016
Same journal

Long-term treatment-free remission in CML after early dasatinib discontinuation due to interstitial pneumonitis.

International journal of hematology·2026
Same journal

Correction to: Low reticulocyte count at infusion is a risk factor for high-grade cytokine release syndrome in chimeric antigen receptor T cell therapy.

International journal of hematology·2026
Same journal

The efficacy of prophylactic tranexamic acid in patients with hematologic malignancy: a systematic review and meta-analysis.

International journal of hematology·2026
Same journal

Current status and challenges of TCR-T cell therapy for AML/MDS.

International journal of hematology·2026
Same journal

Efficacy and safety of maribavir in Japanese patients with post-transplant cytomegalovirus infections: a phase III study.

International journal of hematology·2026
Same journal

Prognostic impact of WT1 dynamics in peripheral blood before and after allogeneic HSCT in patients with AML and MDS.

International journal of hematology·2026
See all related articles

Survivin, an inhibitor-of-apoptosis protein, is crucial for normal cell survival but overexpressed in cancers. Targeting survivin offers a promising therapeutic strategy for malignancies.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Biology

Background:

  • Survivin is a key member of the inhibitor-of-apoptosis protein family.
  • It regulates normal hematopoietic cell proliferation and survival.
  • Aberrant survivin expression is common in various cancers and hematopoietic malignancies.

Purpose of the Study:

  • To review the current research progress on survivin.
  • To highlight survivin's role in cancer.
  • To discuss therapeutic strategies targeting survivin.

Main Methods:

  • Literature review of survivin research.
  • Analysis of survivin's role in normal and malignant cells.
  • Evaluation of in vitro and in vivo studies targeting survivin.

Related Experiment Videos

Main Results:

  • Survivin's dual role in normal cell homeostasis and cancer progression.
  • Demonstration of survivin's aberrant expression in diverse malignancies.
  • Overview of various experimental approaches to inhibit survivin function.

Conclusions:

  • Survivin is a significant therapeutic target in oncology.
  • Targeting survivin presents a viable strategy for cancer treatment.
  • Continued research is essential for developing effective survivin-based therapies.